The patients with ASXL1 mutation have worse OS. The patients with ASXL1 mutation have worse OS compared with patients without ASXL1 mutation (median, 14 months vs 58 months; P = .009; A). The difference was also seen when patients with APL were excluded (median, 14 months vs 34.0 months; P = .022; B) or in patients with intermediate cytogenetics (median, 10 months vs 25.0 months; P = .009; C).